Evidence map›Paper›PMID 31005367›Full record

ArticleBioorganic & medicinal chemistry2019

Targeted delivery of atorvastatin via asialoglycoprotein receptor (ASGPR).

Youxi Zhang, Xinfu Zhang, Chunxi Zeng, Bin Li, Chengxiang Zhang, Wenqing Li, Xucheng Hou, Yizhou Dong

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. A Water-Soluble Polysaccharide fromFoods (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Nanotechnology for the Diagnosis and Treatment of Liver Cancer.International journal of nanomedicine · 2024
    Review
  6. Article
  7. Peptide Drug Conjugates and Their Role in Cancer Therapy.International journal of molecular sciences · 2023
    Review
  8. Drug delivery · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Youxi ZhangDivision of Pharmaceutics & Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH 43210, United States; Department of Pharmacy, The Fourth Affiliated Hospital of China Medical University, No. 4, Chongshan Eastern Road, Shenyang 110032, China.
Xinfu ZhangDivision of Pharmaceutics & Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH 43210, United States; State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian 116024, China.
Chunxi ZengDivision of Pharmaceutics & Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH 43210, United States.
Bin LiDivision of Pharmaceutics & Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH 43210, United States.
Chengxiang ZhangDivision of Pharmaceutics & Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH 43210, United States.
Wenqing LiDivision of Pharmaceutics & Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH 43210, United States.
Xucheng HouDivision of Pharmaceutics & Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH 43210, United States.
Yizhou DongDivision of Pharmaceutics & Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH 43210, United States; Department of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, United States; The Center for Clinical and Translational Science, The Ohio State University, Columbus, OH 43210, United States; The Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, United States; Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University, Columbus, OH 43210, United States; Department of Radiation Oncology, The Ohio State University, Columbus, OH 43210, United States. Electronic address: dong.525@osu.edu.
The Ohio State University · USChina Medical University · CNDalian University · CNLung Institute · US

Funding

Cell-specific and multifunctional drug formulations for in vivo deliveryR35GM119679 · NIGMS · OHIO STATE UNIVERSITY · PI DONG, YIZHOU · 2016 to 2020
$1.9M
NIGMS NIH HHS R35 GM119679
6 · The paper itself

Abstract

Targeted drug delivery platforms can increase the concentration of drugs in specific cell populations, reduce adverse effects, and hence improve the therapeutic effect of drugs. Herein, we designed two conjugates by installing the targeting ligand GalNAc (N-acetylgalactosamine) onto atorvastatin (AT). Compared to the parent drug, these two conjugates, termed G2-AT and G2-K-AT, showed increased hepatic cellular uptake. Moreover, both conjugates were able to release atorvastatin, and consequently showed dramatic inhibition of β-hydroxy-β-methylglutaryl-CoA (HMG-CoA) reductase and increased LDL receptors on cell surface.

Indexed as

AcetylgalactosamineAnimalsAsialoglycoprotein ReceptorAtorvastatinCell Line, TumorHepatocytesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHydroxymethylglutaryl CoA ReductasesLigandsReceptors, LDLSwineAcetylgalactosamineAsialoglycoprotein ReceptorAtorvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsHydroxymethylglutaryl CoA ReductasesLigandsReceptors, LDLAsialoglycoprotein receptorAtorvastatinLigand conjugatesN-AcetylgalactosamineTargeted delivery

Identifiers

PMID31005367
PMCPMC6535107
OpenAlexW2939587695

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.